Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardioangiologica 2006 October;54(5) > Minerva Cardioangiologica 2006 October;54(5):687-93



Publishing options
To subscribe
Submit an article
Recommend to your librarian





Minerva Cardioangiologica 2006 October;54(5):687-93


language: English

Contemporary antithrombotic treatment after coronary stenting in patients with indication for long-term anticoagulation

Rubboli A. 1, Brancaleoni R. 2, Colletta M. 1, Herzfeld J. 3, Sangiorgio P. 1, Di Pasquale G. 1

1 Division of Cardiology Ospedale Maggiore, Bologna, Italy 2 Division of Internal Medicine General Hospital Porretta Terme, Bologna, Italy 3 School of Medicine Karolinska University, Stockholm, Sweden


Aim. Dual antiplatelet treatment with aspirin and a thienopyridine is the antithrombotic treatment recommended after percutaneous coronary intervention with stent implantation (PCI-S). Optimal treatment in patients with an indication for long-term oral anticoagulation (OAC) undergoing PCI-S is currently undefined. The aim of this study was to evaluate the contemporary management of these patients, and determine the safety and the efficacy of the various regimens.
Methods. A systematic review of the literature reporting on this issue was carried out.
Results. The adopted strategies showed substantial variability, and the regimens used included: substitution of OAC for dual antiplatelet therapy in 25-54% of cases, addition to OAC of a single antiplatelet agent in 12-25% and institution of triple therapy with OAC (or low-molecular-weight heparin), aspirin and a thienopyridine in about 60%. OAC was systematically aimed at a lower intensity in 33% of cases, whereas in another 29% this was pursued only when a high hemorrhagic risk was perceived. Both safety and efficacy of the various regimens appeared suboptimal, with a 30-day occurrence of major bleeding and thrombotic complications of 3-7% and 4%, respectively.
Conclusions. Due to the suboptimal safety and/or efficacy of the various regimens adopted, the optimal antithrombotic treatment in patients with an indication for OAC undergoing PCI-S remains to be defined. Since the number of this patient subgroup is foreseen to progressively increase over the next years, large scale registries and clinical trials are warranted.

top of page